A Phase II Trial of the Efficacy and Safety of Tocilizumab for Treatment of Inflammation in the Renal Allograft
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2018
Price : $35 *
At a glance
- Drugs Tocilizumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 10 Oct 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2018.
- 10 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated